Compared with the PDOTs from patients with low TFRC expression, those from patients with high TFRC expression exhibited weaker tumour‐killing effects following anti‐PD‐1 antibody treatment (p < 0.05, Figure 6C). This evidence concerns the gene PDCD1 and neoplasm.